Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Accumulated Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Accumulated Expenses for 10 consecutive years, with $23000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Other Accumulated Expenses rose 283.33% to $23000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $23000.0, a 283.33% increase, with the full-year FY2020 number at $23000.0, up 283.33% from a year prior.
  • Other Accumulated Expenses was $23000.0 for Q4 2020 at Plus Therapeutics, up from $6000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $336000.0 in Q4 2016 to a low of $6000.0 in Q4 2019.
  • A 5-year average of $158200.0 and a median of $201000.0 in 2018 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: crashed 97.01% in 2019, then surged 283.33% in 2020.
  • Plus Therapeutics' Other Accumulated Expenses stood at $336000.0 in 2016, then tumbled by 33.04% to $225000.0 in 2017, then dropped by 10.67% to $201000.0 in 2018, then plummeted by 97.01% to $6000.0 in 2019, then soared by 283.33% to $23000.0 in 2020.
  • Per Business Quant, the three most recent readings for PSTV's Other Accumulated Expenses are $23000.0 (Q4 2020), $6000.0 (Q4 2019), and $201000.0 (Q4 2018).